# Design Therapeutics, Inc. (DSGN) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Design Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/DSGN/mda/fy2025/): filed 2026-03-09; accession 0001193125-26-098491 (https://www.sec.gov/Archives/edgar/data/1807120/000119312526098491/dsgn-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/DSGN/mda/fy2024/): filed 2025-03-10; accession 0000950170-25-035910 (https://www.sec.gov/Archives/edgar/data/1807120/000095017025035910/dsgn-20241231.htm)
- [FY 2023 MD&A](/company/DSGN/mda/fy2023/): filed 2024-03-19; accession 0000950170-24-033492 (https://www.sec.gov/Archives/edgar/data/1807120/000095017024033492/dsgn-20231231.htm)
- [FY 2022 MD&A](/company/DSGN/mda/fy2022/): filed 2023-03-14; accession 0000950170-23-007869 (https://www.sec.gov/Archives/edgar/data/1807120/000095017023007869/dsgn-20221231.htm)
- [FY 2021 MD&A](/company/DSGN/mda/fy2021/): filed 2022-03-10; accession 0000950170-22-003369 (https://www.sec.gov/Archives/edgar/data/1807120/000095017022003369/dsgn-20211231.htm)

Back to /company/DSGN/